Q2 FY2026 · ended Jun 30, 2026 · Revenue $14.72M, +19.8% YoY · Filed Aug 13, 2026
Lensar, Inc. (LNSR) files with the SEC under industry code 3841, Surgical & Medical Instruments & Apparatus. In Q2 of fiscal 2026, the quarter ended Jun 30, 2026, it reported revenue of $14.7 million and net income of $3.5 million. Free cash flow was -$156,000. As of Jun 30, 2026 it held $13.6 million in cash and investments and $2.4 million in total debt.
Revenue
$14.72M
+19.8% vs year-ago quarter
Net income
$3.54M
+300.4% vs year-ago quarter
Operating cash flow
$-127,000
+97.5% vs year-ago quarter
Free cash flow
$-156,000
+96.9% vs year-ago quarter
EPS
$0.10
+166.7% vs year-ago quarter
Dividend per share
None
Shares outstanding
12.29M
+2.9% vs year-ago quarter
Net cash
$11.18M
Q2 FY2026
Operating margin
-15.2%
TTM
Company profile
- Industry
- Surgical & Medical Instruments & Apparatus (SIC 3841)
- Listed as
- LNSR (Nasdaq)
- Fiscal year ends
- December 31
- Incorporated in
- DE
- Headquarters
- Orlando, FL
- SEC filer status
- Non-accelerated filer, Smaller reporting company
- SEC CIK
- 1320350
- Former names
- LensAR Inc (until Jan 14, 2015); LaserSoft Vision Inc (until Jun 16, 2006)
Other Surgical & Medical Instruments & Apparatus companies
- Stryker Corp SYK
- 3M Co MMM
- Boston Scientific Corp BSX
- Becton Dickinson & Co BDX
- Medline Inc. MDLN
- Resmed Inc RMD
- Dexcom Inc DXCM
- Fresenius SE & Co. KGaA FSNUY
All 151 Surgical & Medical Instruments & Apparatus companies
Key figures
Fiscal-year totals from the annual reports; switch to Annual for the full-year view. Balance sheet lines are as of each year end.
| Line | Q2 FY2026 Jun 30, 2026 |
Q1 FY2026 Mar 31, 2026 |
Q4 FY2025 Dec 31, 2025 |
Q3 FY2025 Sep 30, 2025 |
Q2 FY2025 Jun 30, 2025 |
|---|---|---|---|---|---|
| Revenue | $14.7M | $11.7M | $14.3M | $12.8M | $12.3M |
| Operating income | $2.1M | $2.2M | -$4.9M | -$7.6M | -$6.3M |
| Net income | $3.5M | $36.3M | -$1.5M | -$3.7M | -$1.8M |
| Diluted EPS | $0.10 | $0.00 | -$0.12 | -$0.31 | -$0.15 |
| Operating cash flow | -$127,000 | -$4.3M | $618,000 | -$3.5M | -$5.0M |
| Free cash flow | -$156,000 | — | $618,000 | -$3.5M | -$5.1M |
| Total assets | $69.6M | $66.2M | $71.4M | $70.2M | $70.4M |
| Total liabilities | $40.9M | $41.6M | $83.7M | $82.3M | $79.7M |
| Stockholders' equity | $14.9M | $10.8M | -$26.0M | -$25.9M | -$23.1M |
| Cash and investments | $13.6M | $13.5M | $18.0M | $16.9M | $20.3M |
| Total debt | $2.4M | $2.6M | $2.7M | $2.9M | $2.3M |
Recent SEC filings
| Form | Description | Filed | Period |
|---|---|---|---|
| 10-Q | Quarterly report | Aug 13, 2026 | Jun 30, 2026 |
| 8-K |
Current report
Results of operations
|
Aug 13, 2026 | Aug 13, 2026 |
| 8-K |
Current report
Shareholder vote results
|
Aug 10, 2026 | Aug 4, 2026 |
| ARS | Annual report to shareholders | Jun 23, 2026 | Dec 31, 2025 |
| 8-K |
Current report
Officer or director change, Other events
|
May 29, 2026 | May 25, 2026 |
| 10-Q | Quarterly report | May 8, 2026 | Mar 31, 2026 |
All 327 Lensar, Inc. SEC filings
Source: SEC EDGAR filings. This is company-reported data, not investment advice.